Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Apolizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Apolizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Apolizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Apolizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Apolizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Apolizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Apolizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Apolizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Apolizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Apolizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Apolizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Apolizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Apolizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Apolizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Apolizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Apolizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Apolizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Apolizumab. |
| Equol | Equol may increase the thrombogenic activities of Apolizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Apolizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Apolizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Apolizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Apolizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Apolizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Apolizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Apolizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Apolizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Apolizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Apolizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Apolizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Apolizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Apolizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Apolizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Apolizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Apolizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apolizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apolizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Apolizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apolizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Apolizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Apolizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Apolizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apolizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apolizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Apolizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apolizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apolizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Apolizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apolizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Apolizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Apolizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Apolizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apolizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apolizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Apolizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Apolizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Apolizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Apolizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Apolizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Apolizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Apolizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Apolizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Apolizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Apolizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Apolizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Apolizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Apolizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Apolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Apolizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Apolizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Apolizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Apolizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Apolizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Apolizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Apolizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Apolizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Apolizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Apolizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Apolizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Apolizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Apolizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Apolizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Apolizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Apolizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Apolizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Apolizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Apolizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Apolizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Apolizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Apolizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Apolizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Apolizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Apolizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Apolizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Apolizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Apolizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Apolizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Apolizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Apolizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Apolizumab. |